Author:
Schulz Ellina,Hohmann Tim,Hohmann Urszula,Ernestus Ralf-Ingo,Löhr Mario,Dehghani Faramarz,Hagemann Carsten
Reference46 articles.
1. Weidle UH, Birzele F, Kollmorgen G et al (2016) Dissection of the process of brain metastasis reveals targets and mechanisms for molecular-based intervention. Cancer Genomics Proteomics 13(4):245–258
2. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. https://doi.org/10.1056/NEJM200103153441101
3. Mayer IA, Abramson VG, Isakoff SJ et al (2014) Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 32(12):1202–1209. https://doi.org/10.1200/JCO.2013.54.0518
4. Elion DL, Jacobson ME, Hicks DJ et al (2018) Therapeutically active RIG-I agonist induces immunogenic tumor cell killing in breast cancers. Cancer Res 78(21):6183–6195. https://doi.org/10.1158/0008-5472.CAN-18-0730
5. Ekici K, Temelli O, Dikilitas M et al (2016) Survival and prognostic factors in patients with brain metastasis: single center experience. J BUON 21(4):958–963
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献